Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which chemo works better for esophageal cancer? study compares two common drugs

NCT ID NCT07549269

Knowledge-focused Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 25, 2026 · Updated 3 times

Summary

This study looked back at 387 patients with esophageal cancer to compare two chemotherapy drugs, nab-paclitaxel and paclitaxel, given before surgery. The goal was to see which drug leads to better outcomes like complete cancer removal. The study is completed, but results are not yet published.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nab-paclitaxel and paclitaxel (chemotherapy drugs)
What this could lead to
If one drug proves better, it could guide doctors to choose the more effective chemotherapy for esophageal cancer patients before surgery.
What could go wrong
This is a retrospective study, not a controlled trial, so results may be less reliable. It also does not test a new treatment, just compares existing ones.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

387 people

The number who actually took part.

Started

Apr 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This retrospective study included 1877 ESCC patients who underwent esophagectomy at West China Hospital of Sichuan University and two other centers between June 2019 and December 2024. After screening, 387 eligible patients were included.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed diagnosis of esophageal squamous cell carcinoma (ESCC). 2. Patients with resectable or potentially resectable disease based on baseline clinical assessment. Exclusion Criteria: 1. Presence of any untreated malignancy within the past five years, except fully treated cervical carcinoma in situ or basal cell carcinoma/squamous cell skin cancer. 2. Receipt of other neoadjuvant treatments, including chemotherapy, chemoradiotherapy, or chemoradiotherapy combined with immunotherapy. Incomplete medical records. 3. Refusal to participate in follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal cancer

Contacts and locations

Locations

  • Mianzhu People's Hospital（West China Mianzhu Hospital, Sichuan University)

    Mianzhu, Sichuan, 861916, China

  • Suining Central Hospital

    Suining, Sichuan, China

  • West China Hospital

    Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.